AMENDMENT NO. 1 TO THE COMMERCIALIZATION AGREEMENTThe Commercialization Agreement • November 8th, 2022 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledNovember 8th, 2022 Company IndustryThis Amendment No. 1 to the Commercialization Agreement (this “Amendment”) is made and entered into, effective as of September 27, 2022 (“Amendment Effective Date”), by and between Atara Biotherapeutics, Inc. (“Atara”), a Delaware corporation with offices at 611 Gateway Blvd, Suite 900, South San Francisco, CA 94080 and Pierre Fabre Medicament (“Partner”), having its registered office at Les Cauquillous, 81500 Lavaur, France. Atara and Partner are sometimes referred to singly as “Party” and collectively as “Parties.”